CURIS INC
CRIS · XNASCIK 1108205fmd_08DTX62BBW9E7SP7SW2YEPZ9N6Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 10 | 10 | 10 | 11 | 11 | 10 | 10 | 11 | 9 |
| Property operating expenses | – | – | – | – | – | – | – | – | – | – |
| Research and development | 18 | 45 | 24 | 22 | 23 | 35 | 43 | 39 | 39 | 28 |
| Operating income | (58) | (50) | (29) | (24) | (25) | (42) | (53) | (48) | (45) | (6) |
| Interest expense | 3 | 4 | 4 | 1 | 0 | 0 | – | – | – | – |
| Interest and investment income | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 3 | 2 | 0 |
| Other non-operating income (expense) | (2) | (4) | (3) | (8) | (5) | (3) | (4) | 1 | 1 | (2) |
| Income tax expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Net income | (60) | (53) | (33) | (32) | (30) | (45) | (57) | (47) | (43) | (8) |